doi: 10.1080/1354750X.2021.2023219 136 JiFLiZNguyenHYoungNShiPFlemingNet al
use within 12 weeks with bacteriostatic water preservative [7]
Antibodies and reagents The anti--actin (cat#3700), anti--tubulin (cat#3873), anti-SLC7A11 (cat#12691), anti-ER (cat#13258), phospho-Tyr-100 (cat#9411), and phospho-ERK (Thr202/Tyr204) (cat#4370) were purchased from Cell Signaling Technology (Danvers, MA, USA)
Of those reporting no SGLT2i use at baseline, increasing numbers of participants started SGLT2i during the trial, with a greater proportion starting SGLT2i in the placebo (approximately 10% at 18 months and approximately 20% at 36 months) than in the semaglutide group (approximately 5% at 18 months and approximately 10% at 36 months
The consistency of primary, secondary and tertiary prevention definitions in the context of musculoskeletal sports injuries: a rapid review and critical exploration of common terms of usage
The scientific interest in GLP-1 medications for addiction treatment extends beyond alcohol use disorder specifically